Photoactivated Antimicrobial Collagen

光活化抗菌胶原蛋白

基本信息

批准号：
8466990
负责人：
BARBARA Ann SOLTZ
金额：
$ 58.92万
依托单位：
CONVERSION ENERGY ENTERPRISES
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-05-01 至 2015-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8466990
关键词：
Abscess Acute Ambulatory Care Facilities Animals Antibiotics Area Bacteria Bacterial Antibiotic Resistance Bacteriophages Beds Biochemistry Biocompatible Biocompatible Materials Caring Cessation of life Chronic Cicatrix Clinical Research Collagen Collagen Type I Colony-forming units Communities DNA Data Decubitus ulcer Development Devices Doctor of Philosophy Documentation Dose Drug Carriers Effectiveness Electronics Emergency Situation Ensure Environment Escherichia coli Infections Family suidae Film Flavins General Hospitals Generations Genes Genetic Materials Growth Guidelines Healed Hematoma Histopathology Hospitalization Hospitals Human In Vitro Incidence Infection Inpatients Laser Surgery Lasers Lead Legal patent Length of Stay Light Measures Medical Methods Microbial Biofilms Modeling Morbidity - disease rate Mutation Nosocomial Infections Nucleotides Operating Rooms Operative Surgical Procedures Optics Output Oxidation-Reduction Patients Performance Phase Physiologic pulse Plasmids Predisposition Preparation Prevalence Principal Investigator Procedures Process Property Pseudomonas aeruginosa RNA Reaction Reagent Reporting Research Resistance Resistance development Resources Riboflavin Sampling Seroma Source Staphylococcus aureus Sterile coverings Surgical Wound Infection Surgical incisions Surgical wound System Technology Testing Time Tissues Toxic effect Visible Radiation Work Wound Healing Wound Infection antimicrobial antimicrobial drug bacterial resistance bactericide base chromophore controlled release conventional therapy cost design disability experience free radical oxygen healing in vivo methicillin resistant Staphylococcus aureus microbial mortality mouse model novel novel strategies open wound pathogen phase 1 study pre-clinical prevent research study skills technological innovation treatment strategy trend wound

项目摘要

DESCRIPTION (provided by applicant): The significance of this project is the development of a novel photoactivated collagen dressing with demonstrated bactericidal effects, minimal toxic effects and low susceptibility to mechanisms of microbial resistance in an effort to ultimately expand the armamentarium of antimicrobial agents for the management of wound infections. Approximately 2 million patients develop hospital-acquired (nosocomial) infections with surgical wound infections being the most common. It has been reported that 1 of every 24 (4.1%) patients who have inpatient surgery in the US develops a wound infection. These infections are substantial in terms of their impact on morbidity, mortality and resource use. As many as 100,000 deaths and staggering costs of $3.5B annually are associated with wound infections. In the US wound infections increase costs of hospitalization by more than $3,000/patient. While the conventional treatment of infections includes both focused and broad-spectrum antibiotics there has been a continuing and alarming trend of microbial resistance to these agents. This resistance is believed to occur as a result of chromosomal mutation, inductive expression of a latent chromosomal genes or exchange of genetic material via transformation, bacteriophage transduction, or plasmid conjugation. In-vitro and in-vivo experiments were successfully performed during Phase I. It was demonstrated that the light activated dressings significantly inhibits bacterial growth in-vitro, including biofilm scenarios. In addition, the effect is robust, reducing bacterial loads in-vivo in infected incision, wound abscess and pressure ulcer models. Similar results were obtained for Staphylococcus aureus, MRSA, Pseudomonas aeruginosa and Escherichia coli infections. The current proposal specifically aims to further refine the use of photoactivated antimicrobial collagen technology as a wound treatment to augment wound closure and healing, thereby reducing the incidence of acute and chronic wound infections. The studies performed will provide important preclinical results designed to optimize materials for human clinical studies and FDA approval.

描述（由申请人提供）：该项目的重要性是开发一种新型的光活化胶原蛋白敷料，具有杀菌作用，最小的毒性作用和对微生物耐药机制的敏感性低，以最终扩大抗微生物剂的抗微生物抗体，以促进伤口感染的管理。大约有200万患者会出现医院的（医院医院）感染，而手术伤口感染最为常见。据报道，在美国接受住院手术的每24名（4.1％）患者中，有1例会出现伤口感染。这些感染在对发病率，死亡率和资源使用的影响方面很重要。每年多达100,000人死亡和$ 3.5B的惊人费用与伤口感染有关。在美国，伤口感染使住院费用增加了3,000多美元。虽然传统的感染治疗包括聚焦和广谱抗生素，但微生物对这些药物的耐药性持续而令人震惊。据信这种耐药性是由于染色体突变，潜在染色体基因的感应表达或通过转化，噬菌体转导或质粒结合而产生的。在第一阶段中成功进行了体外和体内实验。这证明，光活化的敷料显着抑制了包括生物膜场景在内的维特罗的细菌生长。另外，效果很强，减少感染切口，伤口脓肿和压溃疡模型的细菌载荷。金黄色葡萄球菌，MRSA，铜绿假单胞菌和大肠杆菌感染也获得了相似的结果。当前的提案专门旨在进一步完善光活化的抗菌胶原蛋白技术作为伤口治疗，以增加伤口闭合和愈合，从而减少急性和慢性伤口感染的发生率。进行的研究将提供重要的临床前结果，旨在优化人类临床研究和FDA批准的材料。